Janus Kinase Inhibitor
JAK inhibition ‘promising,’ could reduce steroid use in dermatomyositis
Earlier this year, a group of researchers published data from long-term extension study of tofacitinib in patients with dermatomyositis, demonstrating a “sustained response” to a pan-JAK inhibitor in this population.
FDA approves upadacitinib for non-radiographic axial spondyloarthritis
The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis, marking the sixth indication for the therapy, according to a press release from AbbVie.
Major cardiac events not more common in patients receiving JAK inhibitors vs adalimumab
The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.
B-cell depleting therapies ‘biggest threat’ for reduced SARS-CoV-2 mRNA vaccine response
B-cell depleting agents, glucocorticoids and mycophenolate mofetil have all been associated with reduced antibody responses to SARS-CoV-2 vaccination, noted a presenter at the 2022 Association of Women in Rheumatology Annual Conference.
Immune-related adverse events present ‘double-edged sword,’ need multidisciplinary input
Although oncologists take the lead in cancer management with immunotherapies, rheumatologist input is essential to managing the ensuing immune-related adverse events, which pose challenges to coordinated patient care.
Head-to-head studies ‘would be nice’: More data needed to ascertain JAK inhibitor risks
More trials are needed to fully elucidate the cardiovascular, infection and malignancy risks linked to Janus kinase inhibitors in rheumatoid arthritis, said a presenter at the 2022 Association of Women in Rheumatology annual conference.
TYK2 inhibitors may offer pathway for more comprehensive inflammation therapy
The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.
Novel JAK inhibitor induces ‘dose-related’ response in alopecia areata
Higher doses of a novel Janus kinase inhibitor were associated with improved response over 24 weeks in a cohort of patients with alopecia areata, according to a study.
JAK inhibitors as effective as TNF, IL-6 inhibitors for rheumatoid arthritis
Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.
VIDEO: Momelotinib seems effective in anemic myelofibrosis
CHICAGO — Aaron Thomas Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, spoke with Healio about topline results from the MOMENTUM study presented at ASCO Annual Meeting.